ReNeuron to Participate in the Jefferies 2019 Global Healthcare Conference
LONDON, May 31, 2019 /PRNewswire/ -- ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced that ReNeuron's management team will participate in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 in New York City.
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
SOURCE ReNeuron Group plc
Company Codes: LSE:RENE